Details of the Drug Combinations

General Information of This Drug (ID: DMWA5XP)

Drug Name

KU-60019 DMWA5XP

Synonyms

KU-60019; 925701-49-1; ku60019; 925701-46-8; KU 60019; UNII-IAN358A69K; IAN358A69K; CHEMBL2140173; 2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-N-[5-(6-morpholin-4-yl-4-oxopyran-2-yl)-9H-thioxanthen-2-yl]acetamide; C30H33N3O5S; 2-((2S,6R)-2,6-dimethylmorpholino)-N-(5-(6-morpholino-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl)acetamide; 2-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]-N-{5-[6-(morpholin-4-yl)-4-oxo-4H-pyran-2-yl]-9H-thioxanthen-2-yl}acetamide; MLS006011020; cc-509; SCHEMBL3681453; GTPL8041; EX-A658; DTXSID00580453; AOB3627

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Clinical trial	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
KU-60019 + Marizomib	DC2K552	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
KU-60019 + Idarubicin	DCVBUKV	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]
------------------------------------------------------------------------------------

References

1	Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009 Oct;8(10):2894-902.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.